Eyepoint Pharmaceuticals (NASDAQ:EYPT) Shares Gap Up – Here’s Why

Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) shares gapped up before the market opened on Wednesday . The stock had previously closed at $5.47, but opened at $6.04. Eyepoint Pharmaceuticals shares last traded at $5.97, with a volume of 1,783,505 shares trading hands.

Key Stories Impacting Eyepoint Pharmaceuticals

Here are the key news stories impacting Eyepoint Pharmaceuticals this week:

• Positive Sentiment: Management said the LUGANO Phase 3 failure in wet age-related macular degeneration may have been distorted by nine patients—about 4% of the study—who experienced vision loss unrelated to wet AMD. EyePoint also emphasized favorable secondary endpoints, including lower treatment burden and durable disease control. EyePoint: Sell-Off As Duravyu Fails Head-To-Head Study Vs Eylea May Be Overblown
• Positive Sentiment: The LUCIA Phase 3 trial remains a key potential catalyst, with results expected in the fourth quarter of 2026. A positive outcome could revive confidence in the Duravyu program and support a recovery in EYPT shares. EYPT Stock Plunges 67% After Duravyu Misses Phase III Eye Disease Goal
• Positive Sentiment: Citigroup maintained a buy rating and a $17 price target, implying substantial upside if EyePoint can overcome the clinical setback. Options activity was also elevated, with traders purchasing approximately 3,011 call contracts, suggesting some speculative interest in a rebound.
• Neutral Sentiment: Jefferies retained a buy rating but reduced its target to $8, while JPMorgan reaffirmed a neutral rating. These views indicate that analysts see potential value but have materially lowered expectations after the trial result.
• Negative Sentiment: Duravyu missed the primary endpoint in its head-to-head Phase 3 wet AMD study, triggering a roughly 70% collapse and raising significant uncertainty about the drug’s approval and commercial prospects. EyePoint Is Down After DURAVYU Misses Phase 3 Endpoint
• Negative Sentiment: Several firms became more cautious: RBC downgraded EYPT to hold, Chardan cut its rating to neutral, and Cantor Fitzgerald lowered its rating to neutral. RBC and Chardan both cited $5 price targets, signaling additional downside risk.

Analyst Upgrades and Downgrades

Several research firms have weighed in on EYPT. Jefferies Financial Group dropped their price target on Eyepoint Pharmaceuticals to $8.00 and set a “buy” rating for the company in a research note on Monday. Citigroup reduced their price objective on shares of Eyepoint Pharmaceuticals to $17.00 and set a “buy” rating on the stock in a research report on Tuesday. Chardan Capital downgraded shares of Eyepoint Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $5.00 target price on the stock. in a report on Tuesday. Weiss Ratings lowered shares of Eyepoint Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday. Finally, Stifel Nicolaus assumed coverage on shares of Eyepoint Pharmaceuticals in a report on Thursday, July 16th. They issued a “buy” rating and a $40.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Eyepoint Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $28.11.

Eyepoint Pharmaceuticals Price Performance

The company has a market cap of $521.05 million, a P/E ratio of -1.61 and a beta of 1.76. The firm’s 50-day moving average is $12.97 and its two-hundred day moving average is $13.55.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($1.09) EPS for the quarter, missing the consensus estimate of ($1.01) by ($0.08). Eyepoint Pharmaceuticals had a negative net margin of 10,994.73% and a negative return on equity of 135.81%. The business had revenue of $0.51 million for the quarter, compared to the consensus estimate of $0.45 million. As a group, sell-side analysts expect that Eyepoint Pharmaceuticals, Inc. will post -3.6 EPS for the current year.

Institutional Investors Weigh In On Eyepoint Pharmaceuticals

Institutional investors have recently modified their holdings of the stock. Suvretta Capital Management LLC boosted its holdings in shares of Eyepoint Pharmaceuticals by 26.4% in the 4th quarter. Suvretta Capital Management LLC now owns 7,827,685 shares of the company’s stock worth $143,012,000 after purchasing an additional 1,634,970 shares during the period. Adage Capital Partners GP L.L.C. lifted its position in Eyepoint Pharmaceuticals by 9.7% in the second quarter. Adage Capital Partners GP L.L.C. now owns 6,800,000 shares of the company’s stock worth $63,988,000 after buying an additional 600,000 shares during the last quarter. Federated Hermes Inc. boosted its stake in Eyepoint Pharmaceuticals by 36.3% during the fourth quarter. Federated Hermes Inc. now owns 6,017,433 shares of the company’s stock worth $109,938,000 after buying an additional 1,601,101 shares during the period. Franklin Resources Inc. boosted its stake in Eyepoint Pharmaceuticals by 19.3% during the fourth quarter. Franklin Resources Inc. now owns 4,976,915 shares of the company’s stock worth $90,928,000 after buying an additional 805,031 shares during the period. Finally, Vanguard Group Inc. increased its position in Eyepoint Pharmaceuticals by 27.1% during the fourth quarter. Vanguard Group Inc. now owns 4,822,139 shares of the company’s stock valued at $88,100,000 after acquiring an additional 1,027,623 shares during the last quarter. 99.41% of the stock is owned by institutional investors.

About Eyepoint Pharmaceuticals

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.